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Abstract: The pathogenesis of age-related macular degeneration (AMD) is unclear, but it can 
take either a neovascular/exudative/wet form, characterized by choroidal neovascularization 
(CNV), or a dry form. No treatments are available for the dry form, but there are a number of 
pharmacological interventions that inhibit vascular endothelial growth factor (VEGF), which 
is central to the pathogenesis of CNV and neovascular AMD. Available anti-VEGF agents 
either target all active VEGF isoforms (eg, ranibizumab), or take a more selective approach and 
inhibit only VEGF165 (eg, pegaptantib sodium). Current guidance on their use is equivocal and 
restrictive at best, resulting in associated difﬁ  culties in securing adequate, timely funding for 
treatment. The Moorﬁ  elds Eye Hospital undertook an audit of 70 patients receiving intravitreal 
(ITV) pegaptanib sodium on a pro re nata (prn) dosing schedule. Despite initial funding delays, 
the audit recorded superior treatment outcomes compared with those reported in the VISION 
trials at 12 weeks: 88% of audit patients maintained stable vision, 29% gained vision and 6% 
experienced severe vision loss compared with 70%, 6% and 10% of patients in VISION at 
54 weeks, respectively. The audit indicates a positive correlation between patients with better 
baseline visual acuity (VA) and improved therapeutic beneﬁ  ts, including a greater likelihood of 
both vision gain and vision preservation. Experience at Moorﬁ  elds also suggests that pegaptanib 
sodium is more useful in occult lesions than minimally classic lesions, and clinical experience 
suggests that combination therapies may offer the best approach with anti-VEGF therapies. 
Further randomized clinical trials will help better determine the optimal treatment strategies 
with pegaptanib sodium in neovascular AMD.
Keywords: age-related macular degeneration, choroidal neovascularization, vascular endothelial 
growth factor, pegaptanib sodium, visual outcomes, funding
Introduction
Age-related macular degeneration (AMD) is the leading cause of severe visual loss 
in people aged over 50 years in the developed world (Bressler 2004). Early AMD 
is clinically characterized by yellow deposits, known as drusen, and changes in pig-
mentation of the retina. Late AMD develops when there is an in-growth of new blood 
vessels (a process known as choroidal neovascularization [CNV]) that bleed into the 
subretinal space. This more advanced form of the condition is known as neovascu-
lar/exudative/wet type AMD. Dry AMD describes situations in which the macula 
atrophies (geographic atrophy).
Both these late forms of AMD usually lead to severe loss of central vision, which 
results in patients experiencing difﬁ  culties with tasks such as reading, writing, driving, 
and facial recognition. The visual impairment experienced by elderly sufferers who 
have bilateral AMD can have a severely disabling impact. Furthermore the condition 
predominates in older patients in whom the resultant visual impairment can be com-
pounded by other comorbid disabilities. Visually disabled patients are more prone to 
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falls (Ivers et al 1998), and people with rapidly deteriorating 
vision also tend to experience more depression and anxiety, 
and a reduction in independence, compared with the general 
population, irrespective of their age (Augustin et al 2007).
The Macular Photocoagulation Study Group demonstrated 
that the mean visual acuity (VA) in eyes with untreated subfo-
veal CNV was 20/500 at four years after ﬁ  rst examination for 
the disease (Macular Photocoagulation Study Group 1996). 
Other researchers have noted that the most severe cases of 
bilateral neovascular AMD (VA = 20/800 or worse) result in 
a deterioration of health-related quality of life comparable to 
that resulting from a severe stroke (Williams et al 1998). It is 
of little wonder, therefore, that AMD-related visual impair-
ment and its consequences pose a signiﬁ  cant burden on health 
care utilization (Lotery et al 2007; Soubrane et al 2007). As a 
result of the substantial quality of life and economic burden 
posed by AMD, there is considerable interest in therapies that 
may treat, and even prevent, the disease.
Delaying disease progression
The pathogenesis of AMD is unclear (Guymer and Chong 
2006) and cigarette smoking remains the only widely 
accepted modiﬁ  able risk factor for its primary prevention. 
Patients seeking advice on AMD prevention should be 
encouraged to stop smoking (Kelly et al 2004). However, a 
recent systematic review indicated that there is insufﬁ  cient 
evidence to support the role of dietary antioxidants supple-
ments for the primary prevention of early AMD (Chong 
et al 2007).
A formulation of vitamins C 500 mg and E 400 IU, beta-
carotene 15 mg, and zinc 80 mg (shown to reduce the risk 
of developing advanced AMD by 25% in high-risk patients 
enrolled in the Age-Related Eye Disease Study) is recom-
mended in patients at intermediate risk of AMD, or who have 
advanced AMD in one eye (Age-Related Eye Disease Study 
Research Group [AREDS] 2001). In addition, recent data sug-
gest that high dietary intake of macular xanthophylls lutein 
and zeaxanthin is associated with a lower risk of advanced 
AMD development. Similarly, long-chain polyunsaturated 
fatty acids derived from ﬁ  sh consumption are associated with 
a decreased risk of developing advanced AMD (Age-Related 
Eye Disease Study Research Group 2007). No treatments 
are available for the dry form of AMD.
Pharmacological interventions 
for neovascular AMD
Vascular endothelial growth factor (VEGF) plays a pivotal 
role in the pathogenesis of CNV, the hallmark of wet AMD 
(Kaiser 2006), and the introduction of intravitreal (ITV) 
injections of anti-angiogenic agents targeted against the 
VEGF molecule led to an almost immediate paradigm shift 
in the treatment of the disease.
Pegaptanib sodium
Pegaptanib sodium (Macugen®; Pfizer/OSI/Eyetech 
Pharmaceuticals) is one of two anti-VEGF agents that have 
been approved by the European Agency for the Evalua-
tion of Medicinal Products (EMEA) for the treatment 
of neovascular AMD. It is a pegylated ribonucleic acid 
aptamer that binds human VEGF165. Pegaptanib sodium 
differs from other anti-VEGF therapies in that it binds 
near the heparin-binding domain of VEGF-A, thus pre-
venting VEGF165 and larger isoforms from attaching to the 
VEGF receptors, making it a selective anti-VEGF agent, 
rather than one that targets all active VEGF-A isoforms 
(Gragoudas et al 2004). The VEGF Inhibition Study in 
Ocular Neovascularization (VISION) demonstrated that 
pegaptanib sodium is a safe and efﬁ  cacious treatment 
for neovascular AMD (Gragoudas et al 2004). The study 
comprised 2 concurrent prospective, randomized, double-
blind, placebo-controlled, dose-ranging clinical trials in 
which patients with neovascular AMD received 1 of 3 
doses of pegaptanib sodium ITV or sham injections every 
6 weeks for 48 weeks. Patients were included if they were 
50 years of age or older and had subfoveal CNV second-
ary to AMD with best corrected VA of between 20/40 and 
20/320 in the study eye and 20/800 or better in the other 
eye. At 12 months, 70% of pegaptanib sodium-treated 
patients in VISION lost 15 letters compared with 55% 
of sham-treated patients (p  0.001). In addition, more 
patients in the pegaptanib sodium study arm gained 0 
letters than did sham-treated patients (33% vs 23%, 
respectively; p = 0.003).
Ranibizumab
Ranibizumab (Lucentis®; Genentech, Inc), was the sec-
ond anti-VEGF agent to gain EMEA approval for the 
treatment of neovascular AMD. It is a chimeric molecule 
derived from a murine full-length monoclonal antibody 
(MAb) A4.6.1. The humanized fragment antigen binding 
(FAb) form of the molecule is afﬁ  nity-matured to generate 
ranibizumab (rhuFab V2) (Chen et al 1999). Unlike the 
selective nature of pegaptanib sodium, ranibizumab binds 
to, and inhibits, the biologic activity of all active forms of 
VEGF-A and their active degradation products (Rosenfeld 
et al 2005).Clinical Ophthalmology 2008:2(2) 349
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The efﬁ  cacy of ranibizumab was evaluated in patients 
with minimally classic or occult CNV secondary to AMD 
in the Minimally classic/occult trial of the Anti-VEGF anti-
body Ranibizumab In the treatment of Neovascular AMD 
(MARINA). The double-blind, placebo-controlled trial 
randomized patients to monthly injections of either 0.3 mg 
or 0.5 mg ranibizumab or sham. At 12 months, 95% of ranibi-
zumab-treated patients experienced visual improvement or 
stabilization compared with 62% of those receiving placebo 
at (p  0.0001) (Rosenfeld et al 2006a). More ranibizumab-
treated patients experienced visual improvement of 15 
letters compared with sham-treated patients (p  0.0001). 
In addition, the proportion of patients with 20/40 vision (or 
better) at 12 months increased 3-fold in the ranibizumab-
patient group compared with baseline, whereas the number 
of patients with 20/40 vision (or better) decreased in the 
sham study arm.
Ranibizumab was also investigated in patients with pre-
dominantly classic CNV secondary to AMD treated in the 
anti-VEGF ANtibody for the treatment of predominantly 
classic CHORoidal neovascularization in AMD (ANCHOR) 
study. The 2-year, double-blind, placebo-controlled clinical 
trial randomized patients to monthly treatment regimens 
of either 1–2 doses of ranibizumab and sham verteporﬁ  n 
photodynamic therapy [PDT], or sham injection and verte-
porﬁ  n PDT. At 1 year, approximately 94% (0.3 mg) and 96% 
(0.5 mg) of ranibizumab-treated patients maintained (deﬁ  ned 
as a loss in VA 15 letters) or experienced an improvement 
in vision compared with approximately 64% of patients 
treated with sham injection arm (p  0.0001). A statistically 
signiﬁ  cant difference in VA from baseline to 12 months was 
also seen in the ranibizumab-treated patients compared with 
those receiving PDT alone (Brown et al 2006).
Bevacizumab
The humanized form of ranibizumab is known as bevaci-
zumab (Avastin®; Genentech, Inc). Although bevacizumab 
is approved for the treatment of metastatic colorectal cancer 
and is not indicated for the treatment of neovascular AMD, it 
is currently being prescribed off-label in the ophthalmology 
community (Michels et al 2005). The rationale for its use in 
the eye is based on anecdotal evidence from several observa-
tional studies that suggest it may be an effective treatment for 
neovascular AMD. To date, no adverse events related to the 
drug have been reported (Fung et al 2006; Rosenfeld 2006), 
but further studies and clinical trials are required to establish 
its efﬁ  cacy and safety proﬁ  le in this off-license indication. 
Such trials are ongoing.
Anti-VEGF therapy and clinical 
practice
Budgetary implications
All patients in the pegaptanib sodium and ranibizumab 
clinical trials received a course of treatment, independent 
of patient response. Pegaptanib sodium was administered 
6-weekly and ranibizumab every 4 weeks, both demanding 
treatment schedules that are difﬁ  cult to incorporate in the 
job-plan of a typical medical retina consultant.
In clinical practice, it is not just time, but also cost 
that must be taken into consideration and factored into 
treatment budgets. This is increasingly true as public 
awareness of available therapies reaches an all-time high, 
bringing with it an associated increase in demand for (and 
expectations of) treatment outcomes among patients. 
Therefore, in reality, a pro re nata (prn) dosing schedule 
has to be adopted that is both clinically efﬁ  cacious and 
cost-effective.
Treatment and re-treatment
There are several factors that should be taken into consider-
ation when making treatment and re-treatment decisions in 
an attempt to maximize vision gain. If a clinical trial protocol 
is not in place, clinicians should use both functional and 
anatomic criteria (including VA, clinical examination and 
optical coherence tomography [OCT]) to guide treatment and 
re-treatment decisions (Brown et al 2007). Although there are 
published data on re-treatment criteria, clinical experience 
indicates a need to consider each patient for re-treatment 
individually, based on several local and systemic features, 
in order to maximize the beneﬁ  t-risk ratio (Rosenfeld et al 
2006b; Fung et al 2007). Presented below is data summariz-
ing clinical experience of the use of ITV pegaptanib sodium 
on a prn dosing schedule from Moorﬁ  elds Eye Hospital, 
London, UK.
Clinical experience at Moorﬁ  elds 
Eye Hospital
Procedure for funding
There are two regulatory bodies in the UK that examine the 
clinical and cost-effectiveness of newly licensed treatments 
and provide recommendations for their use. In England 
and Wales the relevant body is the National Institute for 
Health and Clinical Excellence (NICE), whereas Scotland 
is regulated by the Scottish Medicines Consortium (SMC). 
At present, PDT is the only NICE-approved treatment for 
neovascular AMD, approved for patients with subfoveal, Clinical Ophthalmology 2008:2(2) 350
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predominantly classic CNV with a VA between 6/12 and 
6/60. There are approximately 50 designated PDT centers 
in the UK and patients from other hospitals are referred to 
these sites for treatment.
Pegaptanib sodium and ranibizumab are both currently 
under appraisal by NICE for the treatment of neovascular 
AMD. Bevacizumab is not under consideration as it is not 
licensed for use in this indication. Draft NICE guidance on 
the agents was published in June 2007, but recommended 
ranibizumab for patients with predominantly classic CNV in 
the better eye only, and pegaptanib sodium not at all within 
the NHS. Implementation of this restrictive guidance would 
translate into 25% of patients with AMD being eligible for 
treatment and NICE is now re-considering the initial draft 
in conjunction with new economic modeling of the drugs. 
A revised draft is still awaited at the time of writing. In 
contrast, the SMC approved unrestricted use of both pegap-
tanib sodium and ranibizumab for treatment of patients with 
neovascular AMD in Scotland.
While they await the revised NICE recommendations, 
Primary Care Trusts (PCTs) and the Strategic Health Author-
ity (SHA) within each region have started funding the use 
of the agents based on local protocols. As a result, there 
are regional variations in the nature and rate of funding for 
both drugs.
Clinical experience with pegaptanib sodium
Pegaptanib sodium was licensed for use by the EMEA in 
January 2006 and a service was subsequently launched in 
March 2006 at Moorﬁ  elds Eye Hospital, in London, UK. 
Seventy patients were enrolled in the service for treatment.
The ﬁ  rst port of call for a patient who presents with neo-
vascular AMD is often the local optometrist. Most hospitals 
that provide an AMD service have a fast-track referral system 
that aims to ensure patients are seen at the Medical Retina 
Clinic within 2 weeks. The retinal specialist then conﬁ  rms 
the diagnosis, both clinically and with ancillary tests such as 
fundus ﬂ  uorescein angiography (FFA) and/or OCT.
Initially, funding for anti-VEGF treatment in the UK 
was on a named-patient basis and was restricted to patients 
with occult and minimally classic CNV lesions who had 
VA between 6/12 and 6/60 in their second eye. This meant 
that when a medical retinal specialist diagnosed a patient 
with the above criteria, an application for funding for the 
patient was submitted to the local PCT and treatment began 
only after approval was obtained. As the VISION study was 
the ﬁ  rst randomized controlled trial (RCT) published, the 
primary outcome measure adopted in clinical practice was 
that of the VISION study, and treatment was restricted to 
patients with minimally classic and occult CNV with recent 
progression of disease.
Audit methology
A prospective digital database was created before the ser-
vice began and data were collected on all patients from 
baseline.
Pegaptanib sodium care pathway
Baseline clinical examinations included best-corrected VA 
(BCVA), FFA, and OCT examination. All patients had 
BCVA, clinical examination, and OCT every 6 weeks; FFA 
was carried out during every fourth visit. All patients received 
the ﬁ  rst three ITV injections of pegaptanib sodium; thereafter 
at the fourth visit, injections were given if: there was persis-
tent sub-retinal ﬂ  uid (SRF) or intra-retinal ﬂ  uid (IRF) with 
a loss of 5 letters; if new SRF or IRF was present; or if there 
were new signs of disease activity, including an increase in 
lesion size or new hemorrhage. Numerical values of OCT 
thickness (μm) were not considered to assess whether repeat 
treatment was needed.
Aim of the audit
The audit aimed to compare the visual outcome of the 
Moorﬁ  elds patient cohort with those of the patients in the 
VISION study. On this basis, it was hypothesized that 
at 12 weeks: at least 70% of patients should have stable 
vision (loss of 15 letters in the Early Treatment Diabetic 
Retinopathy Study [ETDRS]); 6% should gain vision 
(gain of 15 letters ETDRS); and 10% of treated eyes 
should have severe visual loss (loss of 30 letters ETDRS). 
Waiting times, from funding request to time of treatment, 
were also recorded and assessed within the set standard 
of 2 weeks.
Funding issues
Funding for the therapy was applied on named-patient basis 
to the PCT that served the region to which the patient’s 
general practioner (GP) was situated. The speed of approval 
varied between PCTs and ranged between 3–125 days. As 
anti-VEGF agents are not currently approved for use in 
neovascular AMD, PCTs are under no funding obligations 
at this time. Of the applications submitted, 12% were refused 
funding and 10% received no response. Some PCTs restricted 
funding to certain subgroups of lesion types and range of 
VA. However, more applications are being approved now 
than when the service ﬁ  rst started. Of those patients in whom Clinical Ophthalmology 2008:2(2) 351
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funding was approved, 3% were not treated. The reason for 
this was mainly because the potential for visual stabilization 
was limited, either due to the formation of disciform scar 
and/or because the patient’s vision had already degraded too 
far. Some patients opted for private treatments (self-paid) or 
were too ill to have the treatment.
Performance against standards
A comparison of the audit outcomes and those of the VISION 
study are summarized in Table 1 and Figure 1. Figure 2 
also illustrates the superior visual outcome recorded for the 
Moorﬁ  elds cohort compared with patients in the VISION 
study. It must be stressed that this cohort was given a prn 
dosing schedule and that the ﬁ  nal follow-up was at 42 weeks, 
in contrast to the VISION study in which pegaptanib sodium 
was given every 6 weeks and where the results were analyzed 
at 54 weeks and 102 weeks.
The visual outcomes recorded at the Moorﬁ  elds service 
were better in patients with occult lesions than in those with 
minimally classic lesions (see Figure 3). Six of the 9 patients 
in the cohort who had minimally classic lesions opted for 
treatment with bevacizumab at 6 months because of a lack 
of improvement (or a worsening) in their symptoms.
Combination therapy
Most of the patients receiving pegaptanib sodium during 
the audit were granted funding for ranibizumab when it was 
licensed, due to the superiority of the ANCHOR and MARINA 
trial results compared with those of VISION. In addition, a few 
patients that received initial treatment with pegaptanib sodium 
went on to receive ITV bevacizumab, following a series of 
case-series that suggest bevacizumab may offer greater vision 
improvement. Seven patients were treated with pegaptanib 
sodium following bevacizumab treatment while they awaited 
NHS funding for pegaptanib sodium. Eight patients received 
ranibizumab after pegaptanib sodium therapy.
The follow-up data on those patients who switched 
anti-VEGF therapy are limited to comment on visual out-
comes because patients who received bevacizumab privately, 
and those within the NHS who were switched from pegaptnaib 
sodium to ranibizumab had a mean period of follow-up of 
only 6 weeks.
Adverse events
Of the total 200 injections administered during the audit: 
there were no cases of endophthalmitis, traumatic cataract 
or retinal detachment; 1 patient lost 32 letters after the ﬁ  rst 
injection of pegaptanib sodium due to a large sub-retinal 
hemorrhage; 2 patients safely received ITV pegaptanib 
sodium 2 weeks post myocardiac infaction, and 2 patients on 
warfarin received ITV pegaptanib sodium without event.
Audit recommendations
Clinical standards and outcomes
The pegaptanib sodium visual outcome recorded in the 
Moorﬁ  elds patient cohort were better than those seen in the 
VISION study, and the audit indicates a positive correlation 
between patients with better baseline VA and improved 
therapeutic beneﬁ  ts, including a greater likelihood of both 
vision gain and vision preservation. However, it must be 
conceded that the VISION and Moorﬁ  elds inclusion criteria 
did differ slightly.
Figure 1 Mean change in visual acuity during Moorﬁ  elds audit.
Table 1 Comparison of   VISION study versus Moorﬁ  elds treatment 
outcomes
VA Moorﬁ  elds  VISION  VISION
  0.3 mg Macugen  0.3 mg Macugen  Sham
Stable 88%  70%  55%
Gain 29%  6%  2%
SVL 6%  10%  22%
  42 weeks  54 weeks  54 weeks
 n  = 24  n = 294  n = 296
Abbreviation: SVL, severe visual loss.
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It should be noted that, despite the fact that funding of 
treatment was delayed for some patients, the visual outcomes 
were still superior to those recorded in the VISION study. 
The audit also showed that the average delay for funding at 
6 months following commencement of the service was 43 
days, but that this delay decreased to 21 days at 12 months. 
The reason for the improved waiting time may be due to pres-
sure from increased public awareness of the new treatments 
as well as that of funding agencies. It is anticipated that the 
funding issues will be further resolved following publications 
of the full NICE recommendations.
Organization of patient pathway
The audit identified treatment delays that need to be 
addressed, including a need for better education of patients, 
primary care physicians and optometrists. Secondary care 
providers should establish rapid access AMD clinics to 
fast-track patients who present with neovascular AMD at 
their local optometrist so that they receive their clinical 
examination, FFA, and OCT as a one-stop clinic. Funding 
agencies should allocate resources for the development of 
such services so that prior approval for each patient is not 
required and so that the ﬁ  rst treatment can be initiated as 
soon as the diagnosis is established.
The audit of this service also revealed the need for dedi-
cated personnel and sessions during the treatment and follow-
up of these patients. The maintenance of a prospective database 
also helps to identify patients who fail to attend clinic appoint-
ments, and so aids in subsequent follow up and monitoring of 
potential side-effects associated with these new therapies.
Another important requirement is the need for changes 
to existing infrastructure. The Moorﬁ  elds anti-VEGF service 
is demanding and requires space to carry out investigations 
and also clean rooms for treatment. Advance planning for 
Figure 2 Comparison of VISION study versus Moorﬁ  elds audit visual outcomes.
Figure 3 Change in visual acuity in different choroidal neovascularization subtypes seen in Moorﬁ  elds audit patients.
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space and personnel is required in anticipation of the rapid 
expansion of the service. It is difﬁ  cult to sustain such a 
demanding service and more hub-and-spoke centers need to 
be developed. It is also important that the patients be treated 
and monitored by medical retinal specialists to maximize 
strict adherence to the diagnostic and re-treatment criteria 
for both clinical efﬁ  cacy and cost-effectiveness.
Clinical role for pegaptanib sodium 
in neovascular AMD
Clinical experience at Moorﬁ  elds with pegaptanib sodium 
suggests that the visual outcomes achievable with this selec-
tive VEGF inhibitor at 12 weeks are better in clinical practice 
than was reported from the VISION study, despite the prn 
dosing schedule. Similar results have also been reported 
elsewhere (Quiram et al 2007), combining to raise questions 
as to the validity of the cost-effectiveness data based on the 
VISION study.
The exact role of pegaptanib sodium in the treatment 
of neovascular AMD remains to be explored. The limited 
clinical experience available suggests that combination 
therapies may offer the best approach with these agents. 
The ophthalmology community is certainly impressed by 
the visual gain that may occur following treatment with 
ranibizumab therapy, but concerns over the cardiovascular 
safety of pan-VEGF inhibition persist. The interim report 
of the SAILOR study indicates a slight elevation in the risk 
of stroke in patients with a history of recent strokes follow-
ing treatment with ranibizumab (Rosenfeld et al 2006b). 
As a result, the main role for pegaptanib sodium may be 
in patients with increased cardiovascular risks, including 
patients with recent stroke, myocardiac infarction and other 
thromboembolic phenomena. Pan-VEGF inhibition in 
uncontrolled hypertension may also be contraindicated as 
VEGF is a potent vasodilator that regulates blood ﬂ  ow to 
organs and reduction of VEGF levels results in an increase 
in blood pressure. Luttun and Carmeliet have proposed 
that hypertension and proteinuria directly reﬂ  ect systemic 
VEGF inhibition and could be used as surrogate markers for 
systemic VEGF depletion to sub-critical levels (Luttun and 
Carmeliet 2004). Both hypertension and proteinuria were 
not noted with pegaptanib sodium in the VISION study.
Trials of ranibizumab have provided sufﬁ  cient evidence 
that the therapeutic response to the agent is greatest during 
the ﬁ  rst three months of treatment, when given at monthly 
intervals. Switching the treatment regimen from monthly to 
quarterly injections has been shown to result in a decline in 
initial beneﬁ  t (Rosenfeld et al 2006b). Given that the visual 
gain seen in trials was limited after the ﬁ  rst 3–4 injections 
of ranibizumab, it may be useful to switch patients to pegap-
tanib sodium when there are signs of persistent activity of 
the neovascular lesion without signiﬁ  cant change in VA. It is 
important to compare the effect of a single pan-VEGF inhibi-
tion to initial induction (initial loading dose) with pan-VEGF 
inhibition and then maintenance with pegaptanib sodium. 
Observations from numerous trials involving ranibizumab 
also showed the need to individualize re-treatment regimens, 
based on patient-speciﬁ  c diagnostic monitoring. It is impor-
tant to provide a holistic approach and to update the medical 
history of these patients at each visit.
Conclusions
The optimal treatment strategy with anti-VEGF agents in 
neovascular AMD is yet to be established and requires fur-
ther investigation of existing treatments in both RCTs and 
in clinical practice.
Following its use in clinical practice, experience at 
Moorﬁ  elds Eye Hospital suggests that results following 
treatment with pegaptanib sodium for occult and minimally 
classic CNV may be better than those reported from the 
VISION study despite the use of a prn dosing schedule. These 
data also suggest that pegaptanib sodium may be more use-
ful in slow-growing, occult lesions than aggressive lesions 
with a classic component. Yet this area also requires further 
investigation in order to improve understanding of the precise 
indications for pegaptanib.
An ideal anti-VEGF therapy for CNV should: act speciﬁ  -
cally on the CNV; offer a good safety proﬁ  le; have a low-risk 
route of administration; be effective in all lesion types, and 
(most importantly) result in vision improvement. None of 
the existing anti-VEGF agents meets all these criteria and 
therefore, like cancer therapy, it may be best to pursue an 
individualized induction-maintenance regimen based on 
clinical examination, diagnostic monitoring and medical 
evaluation. Despite the availability of these agents, their 
impact on the rate of blind registration due to neovascular 
AMD remains to be investigated.
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